Federated Hermes
KROS icon

Federated Hermes’s Keros Therapeutics KROS Stock Holding History

Federated Hermes’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.61M Buy
689,229
+34,505
+5% +$533K 0.01% 715
2025
Q4 		$13.3M Buy
654,724
+140,564
+27% +$2.47M 0.02% 551
2025
Q3 		$8.13M Sell
514,160
-139,870
-21% -$2.07M 0.01% 613
2025
Q2 		$8.73M Sell
654,030
-570,109
-47% -$7.7M 0.02% 601
2025
Q1 		$12.5M Buy
1,224,139
+1,099,519
+882% +$12.8M 0.03% 507
2024
Q4 		$1.97M Buy
+124,620
New +$6.48M ﹤0.01% 937
2022
Q3 		– Sell
-74
Closed -$2K – 2192
2022
Q2 		$2K Buy
+74
New +$3.25K ﹤0.01% 1984
2021
Q1 		– Sell
-47,703
Closed -$3.37M – 2294
2020
Q4 		$3.37M Buy
+47,703
New +$3.01M 0.01% 916

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return